Metformin and hepatic carcinogenesis

Cancer Prevention Research

Volumn 5, Issue 4, 2012, Pages 500-502

  Pollak, Michael ^a   Gonzalez Angulo, Ana M ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; LIVER; MALE; METABOLISM; NEOPLASM; NOTE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; METFORMIN; NEOPLASMS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84864841547     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0080     Document Type: Review

References (21)

1. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 2010;3:1060-5.
2. Bhalla K, Hwang BJ, Dewi R, Twaddel W, Goloubeva O, Wong K-K, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res 2012;5:544-52.
3. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-70.
4. Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli LA, Birman E, et al. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res 2012;5:536-43.
5. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-37.
6. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6. (Pubitemid 41780780)
7. Hardie DG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans 2011;39:1-13.
8. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid acid synthase. Endocr Relat Cancer 2010:17;351-60.
9. Li Y, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011;13:376-88.
10. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73. (Pubitemid 44799743)
11. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogeninduced premalignant lesions. Cancer Prev Res 2012;5:562-73.
12. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res 2012;5:355-64.
13. Subramaniam N, Sherman MH, Rao R, Wilson C, Coulter S, Evans RM, et al. Metformin-mediated Bambi expression in hepatic stellate cells induces pro-survival Wnt/b-catenin signaling. Cancer Prev Res 2012;5:553-61
14. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011;105-67.
15. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxy glucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011;10:2350-62.
16. Mankouri J, Tedbury PR, Gretton S, Hughes ME, Griffin SD, Dallas ML, et al. Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci U S A 2010;107:11549-54.
17. Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, et al. AKT/mTOR activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology 2012 Jan 23. doi: 10.1002/hep.25600. [Epub ahead of print].
18. Dombrowski F, Mathieu C, Evert M. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in autoimmune diabetic BB/Pfd rats. Cancer Res 2006;66:1833-43. (Pubitemid 43259970)
19. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.
20. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011;96:2601-8.
21. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.